View Older Stories View More Recent Stories
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $93 at Baird
-
Medtronic, Inc. (MDT) PT Raised to $93 at UBS
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
-
Medtronic (MDT) call put ratio 2.9 calls to 1 put with a focus on November 22 weekly 89 calls into quarter results
-
Medtronic (MDT) November weekly 87 straddle priced into quarter results
-
Medtronic (MDT) Gains, Boston Scientific (BSX) Declines
-
Medtronic (MDT) receives FDA approval of Affera Mapping and Ablation System and Sphere-9™ Catheter
-
Medtronic, Inc. (MDT) PT Raised to $96 at Baird
-
RBC Capital Upgrades Medtronic, Inc. (MDT) to Outperform
-
Medtronic (MDT) short duration October 11 weekly 89 calls active
-
Medtronic (MDT) issues voluntary recall notifying insulin pump users of potential risks of shortened pump battery life
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $90 at Truist Securities
-
Medtronic (MDT) Receives FDA Approval of Expanded MRI Labeling for Medtronic Percept PC and Percept RC, as Well as Medtronic Activa PC, RC and SC
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Piper Sandler Reiterates Overweight Rating on Medtronic, Inc. (MDT)
-
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $94 at Oppenheimer
-
Medtronic, Inc. (MDT) PT Raised to $98 at Mizuho
-
Medtronic, Inc. (MDT) PT Raised to $90 at Baird
-
Medtronic, Inc. (MDT) PT Raised to $106 at Wells Fargo
-
Wolfe Research Reiterates Underperform Rating on Medtronic, Inc. (MDT)
-
Deutsche Bank Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $87 at Stifel
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Midday movers: Lilly, Palo Alto and Fabrinet rise; Lowe's, Boeing fall
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Medtronic hikes fiscal 2025 guidance as Q1 earnings beat expectations
-
Medtronic (MDT) Tops Q1 EPS by 3c, Offers FY25 EPS Guidance
-
Medtronic (MDT) call put ratio 2.5 calls to 1 put into quarter results
-
Barclays Reiterates Overweight Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) August 23 weekly 85 straddle priced into quarter results
-
Medtronic (MDT) Declares $0.70 Quarterly Dividend; 3.3% Yield
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
UBS Upgrades Medtronic, Inc. (MDT) to Neutral
-
Midday movers: UBS, Kellanova rise; Starbucks slips
-
Stifel Downgrades Medtronic, Inc. (MDT) to Hold, 'find it difficult to articulate the “what's next”'
-
Medtronic (MDT) announces FDA approval of Simplera CGM and global partnership with Abbott
-
Medtronic, Inc. (MDT) PT Lowered to $85 at Truist Securities
-
Medtronic, Inc. (MDT) PT Lowered to $82 at Baird
-
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Appoints Karen Parkhill as CFO
-
Stifel Comments on Johnson & Johnson (JNJ) Post EU Robotic Tour: 'JNJ’s laparoscopic surgery business continues to be on the losing end of robotic share gain'
